Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives.
Blood transfusion · 01.03.2023 · 21 (2) · 110-118
DOI: 10.2450/2022.0052-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood transfusion, erschienen am 01.03.2023. Verfasst von Syria Laperche und 11 weiteren Autor:innen. Beteiligte Einrichtung: Etablissement Français du Sang, La Plaine St-Denis, France. Hauptthemen laut MEDLINE: Donor Selection, Blood Component Removal. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: The French health authorities are considering expanding the current selective hepatitis E virus (HEV)-RNA testing procedure to include all donations in order to further reduce transfusion-transmitted HEV infection. Data obtained from blood donors (BDs) tested for HEV-RNA between 2015 and 2021 were used to assess the most efficient nucleic acid testing (NAT) strategy. MATERIALS AND METHODS: Viral loads (VLs) and the plasma volume of blood components, as well as an HEV-RNA dose of 3.85 log IU as the infectious threshold and an assay with a 95% limit of detection (LOD) at 17 IU/mL, were used to assess the proportion of: (i) HEV-RNA-positive BDs that would remain undetected; and (ii) blood components associated with these undetected BDs with an HEV-RNA dose >3.85 log IU, considering 4 NAT options (Individual testing [ID], MP-6, MP-12, and MP-24). RESULTS: Of the 510,118 BDs collected during the study period, 510 (0.10%) were HEV-RNA-positive. Based on measurable VLs available in 388 cases, 1%, 15.2%, 21.8%, and 32.6% of BDs would theoretically pass undetected due to a VL below the LOD of ID, MP-6, MP-12, and MP-24 testing, respectively. All BDs associated with a potentially infectious blood component would be detected with ID-NAT while 13% of them would be undetected with MP-6, 19.6% with MP-12, and 30.4% with MP-24 depending on the plasma volume. No red blood cell (RBC) components with an HEV-RNA dose >3.85 log IU would enter the blood supply, regardless of the NAT strategy used. DISCUSSION: A highly sensitive ID-NAT would ensure maximum safety. However, an MP-based strategy can be considered given that: (i) the risk of transmission is closely related to the plasma volume of blood components; (ii) RBC are the most commonly transfused components and have a low plasma content; and (iii) HEV-RNA doses transmitting infection exceed 4 log IU. To minimise the potential risk associated with apheresis platelet components and fresh frozen plasma, less than 12 donations should be pooled using an NAT assay with a LOD of approximately 20 IU/mL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Etablissement Français du Sang, La Plaine St-Denis, France.
- Unité des Virus Émergents (UVE) Aix-Marseille-IRD 190-Inserm 1207-Marseille, France.
- Etablissement Français du Sang Occitanie, Montpellier, France.
- Infinity, Université Toulouse III, CNRS, INSERM, Toulouse, France.
- Laboratoire de Virologie, Hôpital Purpan, CHU, Toulouse, France.
- Etablissement Français du Sang, Centre Pays de la Loire, Angers, France.
Zitieren
APA
Laperche, S., Maugard, C., Lhomme, S., Lecam, S., Ricard, C., Dupont, I., Richard, P., Tiberghien, P., Abravanel, F., Morel, P., Izopet, J., & Gallian, P. (2023). Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives. Blood transfusion, 21(2), 110-118. https://doi.org/10.2450/2022.0052-22
Vancouver
Laperche S, Maugard C, Lhomme S, Lecam S, Ricard C, Dupont I, et al. Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives. Blood transfusion. 2023;21(2):110-118. doi:10.2450/2022.0052-22
BibTeX
@article{Laperche2023,
author = {Laperche, Syria and Maugard, Claude and Lhomme, Sébastien and Lecam, Sophie and Ricard, Céline and Dupont, Isabelle and Richard, Pascale and Tiberghien, Pierre and Abravanel, Florence and Morel, Pascal and Izopet, Jacques and Gallian, Pierre},
title = {Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives},
journal = {Blood transfusion},
year = {2023},
volume = {21},
number = {2},
pages = {110--118},
doi = {10.2450/2022.0052-22}
}
EUVIMED